The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_004004.5(GJB2):c.235delC (p.Leu79Cysfs)

CA127025

17014 (ClinVar)

Gene: GJB2
Condition: nonsyndromic genetic deafness
Inheritance Mode: Autosomal recessive inheritance
UUID: eda5030c-9ccf-4b14-bada-077b25b2562c
Approved on: 2018-09-14
Published on: 2019-07-17

HGVS expressions

NM_004004.5:c.235del
NM_004004.5:c.235delC
NM_004004.5(GJB2):c.235delC (p.Leu79Cysfs)
NC_000013.11:g.20189349del
CM000675.2:g.20189349del
NC_000013.10:g.20763488del
CM000675.1:g.20763488del
NC_000013.9:g.19661488del
NG_008358.1:g.8629del
NM_004004.6:c.235del
ENST00000382844.1:c.235del
ENST00000382848.4:c.235del
More

Pathogenic

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Conflicting Evidence"
Met criteria codes 4
PVS1 PM3_Very Strong BS1 PS3_Moderate
Not Met criteria codes 3
PP3 PM2 BA1

Evidence Links 3

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hearing Loss VCEP
The filtering allele frequency of the p.Leu79CysfsX3 variant in the GJB2 gene is 0.55% (121/ 18870) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BS1 code will not contribute to the overall classification. The p.Leu79CysfsX3 variant in GJB2 is predicted to cause a premature stop codon in the only exon of the gene, leading to absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 10983956, 10633133). A dye transfer assay, a functional study, has shown that the variant impacts protein function (PS3_M; PMID: 12352684). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS3_M, BS1.
Met criteria codes
PVS1
There are no alternate transcripts, the variant should results in NMD and lack of protein.
PM3_Very Strong
This variant was identified in >10 individuals with a pathogenic variant in trans. See the individuals publication notes below for case counts.

BS1
Although the MAF (using the ExAC FAF) is .38% in East Asians, BS1 is not contributing to the overall pathogenicity because this variant is on the HL ClinGen CDWG exclusion list.
PS3_Moderate
A dye transfer assay demonstrated that there was no dye transfer in cells transfected with the c.235delC variant.

Not Met criteria codes
PP3
No splicing change predicted by MaxEntScan.
PM2
Although the MAF (using the ExAC FAF) is .38% in East Asians, BS1 is not contributing to the overall pathogenicity because this variant is on the HL ClinGen CDWG exclusion list.
BA1
Although the MAF (using the ExAC FAF) is .38% in East Asians, BS1 is not contributing to the overall pathogenicity because this variant is on the HL ClinGen CDWG exclusion list.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.